50% of the Revenue Contribution by the Leading Players
The hypoparathyroidism treatment market is largely dominated by the major players, who are competing on the basis of market penetration and distribution. The consolidated nature of the hypoparathyroidism treatment market increases the profitability. Factors such as poor efficacy and efficiency of the treatment are hampering the adoption of hypoparathyroidism treatment. However, the growing awareness regarding hypoparathyroidism treatmentand number of thyroid surgeries are expected to create growth opportunities for the manufacturers operating in the global hypoparathyroidism treatment market. Shire-NPS Pharmaceuticals, Inc., EnteraBio Ltd., and Teva Pharmaceutical Industries Ltd. hold more than 50% revenue share in the global hypoparathyroidism treatment market. The growth of the global hypoparathyroidism treatment market is primarily driven by growing prevalence of hypoparathyroidism and increasing number of thoracic surgeries and incidence of cancer. Thedevelopment of healthcare infrastructure across the globe coupled with governmental support for hypoparathyroidism treatment is expected to drive the growth of the hypoparathyroidism treatment market. The companies operating in the market are involved in developing new experimental hypoparathyroidism treatment drugs.
Increasing Number of Thoracic Surgeries and Incidence of Cancer
The growing screening rates, increasing number of thoracic surgeries and incidence of cancer are expected to be the prime factors driving the growth of the hypoparathyroidism treatment market. Thyroid or neck surgery is associated with hypoparathyroidism, owing to damage to the parathyroid glands. The number of thyroidectomies in the U.S. reflects 39% increase from 2007 to 2015. This indicates transient post-surgical hypoparathyroidism, which can become permanent in about 25% of cases. The growing incidence of head & neck and thyroid cancers is the other factor expected to drive the growth of the market.
Increasing investments in the research and development coupled with the development of biologics is expected to generate momentum and growth opportunities for the hypoparathyroidism treatment market.Read More On www.futuremarketinsights.com